New treatments and outcomes in peritoneal carcinomatosis

Terence C Chua, Winston Liauw and David L Morris
Med J Aust 2009; 191 (1): . || doi: 10.5694/j.1326-5377.2009.tb02662.x
Published online: 6 July 2009

Evidence-based therapies offer hope of prolonged survival for selected patients with this disease

There is now a substantial body of published evidence of the survival benefits conferred by cytoreductive surgery (peritonectomy) and perioperative intraperitoneal chemotherapy comprising hyperthermic intraperitoneal chemotherapy and early postoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis. The technique of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is described in the Box. Here, we, the clinicians at the St George Hospital Peritoneal Surface Malignancy Program, who have had more than 12 years of experience in this treatment, provide a review of this topic.

  • Terence C Chua1
  • Winston Liauw2
  • David L Morris1

  • 1 Department of Surgery, University of New South Wales, Sydney, NSW.
  • 2 Cancer Care Centre, St George Hospital, Sydney, NSW.



remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.